Tag #Oesophageal Cancer

Showing 1 to 4 of 4 results

smh.com.au

🌐 90% Global Worthiness

Jun 5, 10:14

PromarkerEso Blood Test Shows High Accuracy in Detecting Oesophageal Cancer

Proteomics International Laboratories' PromarkerEso blood test for oesophageal cancer showed 91.4% accuracy in detecting the cancer and 98.9% accuracy in identifying those without it in a 259-person study, exceeding the accuracy of existing tests and paving the way for commercial release.

PromarkerEso Blood Test Shows High Accuracy in Detecting Oesophageal Cancer

Proteomics International Laboratories' PromarkerEso blood test for oesophageal cancer showed 91.4% accuracy in detecting the cancer and 98.9% accuracy in identifying those without it in a 259-person study, exceeding the accuracy of existing tests and paving the way for commercial release.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the clinical significance of PromarkerEso's high accuracy in detecting oesophageal cancer and correctly identifying those without it?

Proteomics International Laboratories announced the successful clinical trial results of its PromarkerEso blood test for oesophageal cancer, achieving 91.4% accuracy in detecting the cancer and 98.9% accuracy in correctly identifying those without it. This non-invasive test offers a significant improvement over current methods like endoscopy, which are costly and uncomfortable.

dailymail.co.uk

🌐 85% Global Worthiness

Feb 3, 19:11

UK Oesophageal Cancer Rate Four Times Higher Than Italy's

The UK has a drastically higher rate of oesophageal cancer than other European countries, with 14.2 new cases per 100,000 people annually compared to 3.5 in Italy; this is partly due to late diagnosis as patients often mistake symptoms for heartburn, resulting in approximately 8,000 deaths per year.

UK Oesophageal Cancer Rate Four Times Higher Than Italy's

The UK has a drastically higher rate of oesophageal cancer than other European countries, with 14.2 new cases per 100,000 people annually compared to 3.5 in Italy; this is partly due to late diagnosis as patients often mistake symptoms for heartburn, resulting in approximately 8,000 deaths per year.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do lifestyle factors and delayed diagnosis contribute to the high mortality rate of oesophageal cancer in the UK?

The UK's high oesophageal cancer rate is linked to late diagnosis, often due to patients misinterpreting symptoms like heartburn. Lifestyle factors such as smoking, excessive alcohol consumption, obesity, and regularly consuming very hot drinks increase the risk, and about three in five cases are potentially preventable.

smh.com.au

🌐 85% Global Worthiness

Apr 22, 10:15

Proteomics Secures $4.5M to Launch Novel Diagnostic Blood Tests

Proteomics International Laboratories secured $4.5 million to launch three novel blood tests (PromarkerD, PromarkerEso, PromarkerEndo) across Australia and the US, aiming to address significant unmet needs in diabetic kidney disease, oesophageal cancer, and endometriosis diagnosis.

Proteomics Secures $4.5M to Launch Novel Diagnostic Blood Tests

Proteomics International Laboratories secured $4.5 million to launch three novel blood tests (PromarkerD, PromarkerEso, PromarkerEndo) across Australia and the US, aiming to address significant unmet needs in diabetic kidney disease, oesophageal cancer, and endometriosis diagnosis.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How will the launch of PromarkerD specifically affect the diagnosis and treatment of diabetic kidney disease?

The funding will accelerate the commercialization of Proteomics' diagnostic tests, targeting substantial markets. PromarkerD, for instance, addresses the significant global burden of diabetic kidney disease, costing the US medical industry alone an estimated $130 billion annually. The high accuracy and early detection capabilities of these tests position Proteomics for substantial growth.

smh.com.au

🌐 85% Global Worthiness

Dec 16, 07:09

Proteomics International Secures \$2.16 Million R&D Rebate for Diagnostic Blood Tests

Proteomics International secured a \$2.16 million Australian R&D tax rebate to commercialize its innovative blood tests for diabetic kidney disease, endometriosis, and esophageal cancer, leveraging a \$4.95 million R&D investment and aiming for US market entry.

Proteomics International Secures \$2.16 Million R&D Rebate for Diagnostic Blood Tests

Proteomics International secured a \$2.16 million Australian R&D tax rebate to commercialize its innovative blood tests for diabetic kidney disease, endometriosis, and esophageal cancer, leveraging a \$4.95 million R&D investment and aiming for US market entry.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the \$2.16 million R&D tax rebate on Proteomics International and the Australian healthcare landscape?

Proteomics International received a \$2.16 million R&D tax rebate from the Australian government. This funding will support the commercial launch of its novel blood tests for diabetic kidney disease, endometriosis, and esophageal cancer. The company plans to use the funds to establish a US laboratory and pursue FDA accreditation.

Showing 1 to 4 of 4 results